While NRF2 signaling activates HIF-1 in several cancer types [12], studies of the anti-inflammatory drug andrographolide in endothelial cells revealed interactions between NRF2 and the PHDs that modulate HIF-1 [59]. This evidence concerns the gene HIF1A and cancer.